Developer docs
API playgroundTry for free, no card

Search company profiles

EG Labo

Full company profile

uuid000q3qx

Namestring
EG Labo
Legal namestring
EG LABO - Laboratoires EuroGenerics
Websiteurl
eglabo.fr
Company typeenum
Private
Founded yearint
1996
Descriptiontext

EG Labo (legally Laboratoires EuroGenerics SAS) is a French pharmaceutical laboratory founded in 1996 and headquartered in Issy-les-Moulineaux, operating as a wholly-owned subsidiary of Germany's STADA Arzneimittel AG. The company commercializes over 820 pharmaceutical products across three pillars: specialty generic medicines (the third-largest generic portfolio in the French market), consumer health/OTC products including the Mitosyl and SyntholOral brands, and biosimilars across rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic therapeutic areas. The company reports 40 million units sold annually through its 103 employees in France and serves pharmacies, physicians, pharmacists, and end patients via a sales-led go-to-market focused on tailored strategies for healthcare professionals.

The underlying technology is traditional pharmaceutical product development and regulatory-compliant commercialization rather than a proprietary digital platform; EG Labo relies on STADA Group's R&D pipeline and biosimilar development capabilities rather than independent proprietary technology assets. Revenue mechanics are generated through pharmacy procurement of prescription generics, OTC consumer health products, and biosimilars, all distributed through the French pharmacy network under regulated French national health system pricing. The company's commercial moat rests on portfolio breadth (covering all major therapeutic classes), 29 years of pharmacy channel relationships, and STADA Group's regulatory and biosimilar expertise.

EG Labo's strategic posture is defensive on generics scale and offensive on biosimilars, evidenced by the March 2025 launch of Ximluci (ranibizumab biosimilar), expansion of its biosimilar portfolio to four commercialized products, and proactive pharmacovigilance investments such as the December 2025 valproate pregnancy prevention program update. The company is also investing in HR practices, earning Top Employer France 2026 certification for the first time, suggesting organizational development aligned with STADA's broader European growth strategy.

Short descriptiontext

EG Labo is a French pharmaceutical laboratory and wholly-owned subsidiary of STADA Group that commercializes the third-largest generic medicines portfolio in France, OTC consumer health products, and biosimilars through the French pharmacy network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIssy-les-moulineaux, France
HQ citystring
Issy-les-moulineaux
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, biosimilar medicines, OTC consumer health, pharmaceutical manufacturing, family health products
Industry2 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceuticals
TypeOne Time License
Description

EG Labo operates as a generic pharmaceutical laboratory with the third largest generic portfolio in the French market, offering specialty generics covering major therapeutic classes. Revenue is generated through pharmacy sales of prescription generic medications.

eglabo.fr
2OTC/Consumer Healthcare
TypeOne Time License
Description

EG Labo develops over-the-counter medicines, non-reimbursable reference products, and family health brands including skincare, dietary supplements, cosmetics, and medical devices sold through pharmacies.

eglabo.fr
3Biosimilars
TypeOne Time License
Description

As part of STADA Group, EG Labo commercializes biosimilar medications in France, currently with four biosimilars available, focusing on rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic therapeutic areas.

eglabo.fr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EG Labo is a French pharmaceutical laboratory that manufactures and distributes a broad portfolio of generic medicines, over-the-counter (OTC) consumer health products, and biosimilars. The company holds the third largest generic drug portfolio in the French market, covering all major therapeutic classes with more than 820 products and approximately 40 million units sold annually. Its product range is sold exclusively through French pharmacies and includes specialty generics, family health brands, skincare, dietary supplements, cosmetics, and medical devices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 40 million units sold per year across 820 products
+2 more records
Product overview1 text field

EG Labo (Laboratoires EuroGenerics) is a pharmaceutical company and subsidiary of STADA Group, offering a comprehensive portfolio of generic medications, consumer health products, non-reimbursable reference drugs, and biosimilars. The product portfolio includes three main lines: (1) Spécialités Génériques EG - the third-largest generic drug range in the French market; (2) Santé Grand Public - OTC medications, reference specialties, skincare, supplements, cosmetics, and medical devices; and (3) Biosimilaires - biosimilar medications across rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic areas. The company commercializes over 820 products with 40 million units sold annually, supported by 103 employees and 29 years of experience.

Product and service5 records
1Spécialités Génériques EG
CategoryGeneric Pharmaceuticals
Description

EG Labo's core generic pharmaceuticals portfolio, comprising the third-largest range of generic drugs in the French market and covering all major therapeutic classes for dispensing through pharmacies.

2Santé Grand Public
CategoryConsumer Health / OTC
Description

Consumer health product line offering OTC medications, non-reimbursable reference drugs, family health brands, skincare products, dietary supplements, cosmetics, and medical devices sold through French pharmacies.

3Biosimilaires
CategoryBiosimilar Medicines
Description

Biosimilar medications across multiple therapeutic areas including rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic treatments, with four biosimilars currently commercialized in France.

4Mitosyl
CategoryConsumer Health Product
Description

Well-known family health product brand under the EG Labo portfolio, focused on baby care products including creams, roll-on, and wipes.

5SyntholOral
CategoryConsumer Health Product
Description

Consumer health brand for oral health products distributed in France through the pharmacy network.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EG Labo is a wholly-owned subsidiary of STADA Arzneimittel AG, a German pharmaceutical company headquartered in Bad Vilbel, Germany. STADA operates with three strategic pillars: Consumer Healthcare, Generics, and Specialty products. EG Labo represents the French operations of the STADA Group, benefiting from the group's portfolio, R&D capabilities, and biosimilar development expertise. STADA reported €4.3 billion in adjusted revenue in 2025 with 11,749 employees worldwide.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biogaran is the leading French generic pharmaceutical laboratory and a subsidiary of Servier. It directly competes with EG Labo for pharmacy shelf space across the same generic therapeutic classes in the French market, operating an identical pharmacy-led distribution model.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical company with significant French operations (Teva Santé). It competes directly with EG Labo in generic medicines across the same therapeutic classes while also offering biosimilars, OTC and specialty products at a global scale.

3Sandoz
TypeBroad incumbent
Description

Sandoz is the global leader in generics and biosimilars, spun off from Novartis in 2023. It is a major peer in both generic pharmaceuticals and biosimilars, including the same therapeutic categories EG Labo addresses (immunology, oncology).

4Arrow Génériques (Aurobindo)
TypeDirect peer
Description

Arrow Génériques is one of the leading French generic pharmaceutical companies and part of Aurobindo Group. It competes head-to-head with EG Labo in the French generic market with comparable portfolio breadth and a pharmacy distribution model.

5Cristers
TypeDirect peer
Description

Cristers is a French generic pharmaceutical laboratory offering a broad portfolio across therapeutic classes. It competes directly with EG Labo for the same pharmacy customers with a similar price-led generic value proposition.

TypeDirect peer
Description

Zentiva is a major European generic and OTC pharmaceutical company headquartered in Prague, with significant presence in France. It competes with EG Labo across generics and OTC consumer health products across similar therapeutic areas.

TypeBroad incumbent
Description

Viatris (formed by Mylan-Upjohn merger) is a global pharmaceutical company with a strong generics franchise including French operations. It is comparable to EG Labo in generics and biosimilars but at much larger scale across multiple geographies.

TypeEmerging player
Description

Krka is a Slovenian generic pharmaceutical company with significant European footprint. It overlaps with EG Labo in generic prescription medicines and is expanding in biosimilars, making it a comparable specialty generic manufacturer in European markets.

TypeOthers
Description

STADA is EG Labo's parent company and the relevant comparison point for the broader portfolio strategy, R&D and biosimilar capabilities. As the same group, STADA represents the full upstream source of products and capabilities that flow down to EG Labo.

10Almus Pharmaceuticals
TypeRegional player
Description

Almus is a European generics brand focused on pharmacy-channel generic medicines. While smaller in France, it operates with a comparable pharmacy-only distribution model and similar generic portfolio positioning, making it an adjacent competitive reference.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EG Labo

Generic Pharmaceuticalseglabo.fr

EG Labo is a French pharmaceutical laboratory and wholly-owned subsidiary of STADA Group that commercializes the third-largest generic medicines portfolio in France, OTC consumer health products, and biosimilars through the French pharmacy network.

What EG Labo does

EG Labo (legally Laboratoires EuroGenerics SAS) is a French pharmaceutical laboratory founded in 1996 and headquartered in Issy-les-Moulineaux, operating as a wholly-owned subsidiary of Germany's STADA Arzneimittel AG. The company commercializes over 820 pharmaceutical products across three pillars: specialty generic medicines (the third-largest generic portfolio in the French market), consumer health/OTC products including the Mitosyl and SyntholOral brands, and biosimilars across rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic therapeutic areas. The company reports 40 million units sold annually through its 103 employees in France and serves pharmacies, physicians, pharmacists, and end patients via a sales-led go-to-market focused on tailored strategies for healthcare professionals.

The underlying technology is traditional pharmaceutical product development and regulatory-compliant commercialization rather than a proprietary digital platform; EG Labo relies on STADA Group's R&D pipeline and biosimilar development capabilities rather than independent proprietary technology assets. Revenue mechanics are generated through pharmacy procurement of prescription generics, OTC consumer health products, and biosimilars, all distributed through the French pharmacy network under regulated French national health system pricing. The company's commercial moat rests on portfolio breadth (covering all major therapeutic classes), 29 years of pharmacy channel relationships, and STADA Group's regulatory and biosimilar expertise.

EG Labo's strategic posture is defensive on generics scale and offensive on biosimilars, evidenced by the March 2025 launch of Ximluci (ranibizumab biosimilar), expansion of its biosimilar portfolio to four commercialized products, and proactive pharmacovigilance investments such as the December 2025 valproate pregnancy prevention program update. The company is also investing in HR practices, earning Top Employer France 2026 certification for the first time, suggesting organizational development aligned with STADA's broader European growth strategy.

EG Labo firmographics

Firmographics
Name
EG Labo
Legal name
EG LABO - Laboratoires EuroGenerics
Website
https://eglabo.fr
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
EG Labo is a French pharmaceutical laboratory and wholly-owned subsidiary of STADA Group that commercializes the third-largest generic medicines portfolio in France, OTC consumer health products, and biosimilars through the French pharmacy network.
Ownership category
akta.pro rank

EG Labo industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Biosimilar medicines
  • OTC consumer health
  • Pharmaceutical manufacturing
  • Family health products

Where EG Labo is headquartered

Location

Headquarters

HQ city
Issy-les-moulineaux
HQ country
France
HQ region
Europe

Offices1 record

Markets served

EG Labo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic Pharmaceuticals: EG Labo operates as a generic pharmaceutical laboratory with the third largest generic portfolio in the French market, offering specialty generics covering major therapeutic classes. Revenue is generated through pharmacy sales of prescription generic medications.
  2. OTC/Consumer Healthcare: EG Labo develops over-the-counter medicines, non-reimbursable reference products, and family health brands including skincare, dietary supplements, cosmetics, and medical devices sold through pharmacies.
  3. Biosimilars: As part of STADA Group, EG Labo commercializes biosimilar medications in France, currently with four biosimilars available, focusing on rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

EG Labo product offering

Product offering

Core offering

EG Labo is a French pharmaceutical laboratory that manufactures and distributes a broad portfolio of generic medicines, over-the-counter (OTC) consumer health products, and biosimilars. The company holds the third largest generic drug portfolio in the French market, covering all major therapeutic classes with more than 820 products and approximately 40 million units sold annually. Its product range is sold exclusively through French pharmacies and includes specialty generics, family health brands, skincare, dietary supplements, cosmetics, and medical devices.

Product overview

EG Labo (Laboratoires EuroGenerics) is a pharmaceutical company and subsidiary of STADA Group, offering a comprehensive portfolio of generic medications, consumer health products, non-reimbursable reference drugs, and biosimilars. The product portfolio includes three main lines: (1) Spécialités Génériques EG - the third-largest generic drug range in the French market; (2) Santé Grand Public - OTC medications, reference specialties, skincare, supplements, cosmetics, and medical devices; and (3) Biosimilaires - biosimilar medications across rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic areas. The company commercializes over 820 products with 40 million units sold annually, supported by 103 employees and 29 years of experience.

Differentiator

Problem solved

Functional benefit

Products and services

  • Spécialités Génériques EG EG Labo's core generic pharmaceuticals portfolio, comprising the third-largest range of generic drugs in the French market and covering all major therapeutic classes for dispensing through pharmacies.
  • Santé Grand Public Consumer health product line offering OTC medications, non-reimbursable reference drugs, family health brands, skincare products, dietary supplements, cosmetics, and medical devices sold through French pharmacies.
  • Biosimilaires Biosimilar medications across multiple therapeutic areas including rheumatology, gastroenterology, dermatology, ophthalmology, oncology, and antithrombotic treatments, with four biosimilars currently commercialized in France.
  • Mitosyl Well-known family health product brand under the EG Labo portfolio, focused on baby care products including creams, roll-on, and wipes.
  • SyntholOral Consumer health brand for oral health products distributed in France through the pharmacy network.

Quantifiable outcome

  • 40 million units sold per year across 820 products
  • +2 more outcomes

Companies that use EG Labo

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

EG Labo technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

EG Labo partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • STADA Group (Groupe STADA)coreStrategic or Co-development PartnerEG Labo is a wholly-owned subsidiary of STADA Arzneimittel AG, a German pharmaceutical company headquartered in Bad Vilbel, Germany. STADA operates with three strategic pillars: Consumer Healthcare, Generics, and Specialty products. EG Labo represents the French operations of the STADA Group, benefiting from the group's portfolio, R&D capabilities, and biosimilar development expertise. STADA reported €4.3 billion in adjusted revenue in 2025 with 11,749 employees worldwide.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

EG Labo competitors and assessment

Company assessment

Direct peers

  • Biogaran: Biogaran is the leading French generic pharmaceutical laboratory and a subsidiary of Servier. It directly competes with EG Labo for pharmacy shelf space across the same generic therapeutic classes in the French market, operating an identical pharmacy-led distribution model.
  • Arrow Génériques (Aurobindo): Arrow Génériques is one of the leading French generic pharmaceutical companies and part of Aurobindo Group. It competes head-to-head with EG Labo in the French generic market with comparable portfolio breadth and a pharmacy distribution model.
  • Cristers: Cristers is a French generic pharmaceutical laboratory offering a broad portfolio across therapeutic classes. It competes directly with EG Labo for the same pharmacy customers with a similar price-led generic value proposition.
  • Zentiva: Zentiva is a major European generic and OTC pharmaceutical company headquartered in Prague, with significant presence in France. It competes with EG Labo across generics and OTC consumer health products across similar therapeutic areas.

Broad incumbents

  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical company with significant French operations (Teva Santé). It competes directly with EG Labo in generic medicines across the same therapeutic classes while also offering biosimilars, OTC and specialty products at a global scale.
  • Sandoz: Sandoz is the global leader in generics and biosimilars, spun off from Novartis in 2023. It is a major peer in both generic pharmaceuticals and biosimilars, including the same therapeutic categories EG Labo addresses (immunology, oncology).
  • Mylan/Viatris: Viatris (formed by Mylan-Upjohn merger) is a global pharmaceutical company with a strong generics franchise including French operations. It is comparable to EG Labo in generics and biosimilars but at much larger scale across multiple geographies.

Emerging players

  • Krka: Krka is a Slovenian generic pharmaceutical company with significant European footprint. It overlaps with EG Labo in generic prescription medicines and is expanding in biosimilars, making it a comparable specialty generic manufacturer in European markets.

Others

  • Stada Arzneimittel AG (parent): STADA is EG Labo's parent company and the relevant comparison point for the broader portfolio strategy, R&D and biosimilar capabilities. As the same group, STADA represents the full upstream source of products and capabilities that flow down to EG Labo.

Regional players

  • Almus Pharmaceuticals: Almus is a European generics brand focused on pharmacy-channel generic medicines. While smaller in France, it operates with a comparable pharmacy-only distribution model and similar generic portfolio positioning, making it an adjacent competitive reference.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

EG Labo social profiles

Digital presence

EG Labo compliance and trust

Trust signal

Compliance3 records

EG Labo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EG Labo leadership team

Management profile

Number of profiles

Profiles6 records

EG Labo subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

EG Labo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EG Labo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EG Labo

What does EG Labo do?

EG Labo is a French pharmaceutical laboratory that manufactures and distributes a broad portfolio of generic medicines, over-the-counter (OTC) consumer health products, and biosimilars. The company holds the third largest generic drug portfolio in the French market, covering all major therapeutic classes with more than 820 products and approximately 40 million units sold annually. Its product range is sold exclusively through French pharmacies and includes specialty generics, family health brands, skincare, dietary supplements, cosmetics, and medical devices.

Is EG Labo a public or private company?

EG Labo is a private company. It is classified as corporate owned and is currently operating.

When was EG Labo founded?

EG Labo was founded in 1996. It employs 101 to 250 people.

Where is EG Labo based?

EG Labo is headquartered in Issy-les-moulineaux, France, in the Europe region.

How does EG Labo make money?

Three revenue lines are on record. Generic Pharmaceuticals are the primary driver. The others are OTC/Consumer Healthcare and biosimilars.

Who are EG Labo's main competitors?

Direct peers on record are Biogaran, Arrow Génériques (Aurobindo), Cristers and Zentiva. Broad incumbents are Teva Pharmaceutical Industries, Sandoz and Mylan/Viatris. Krka is listed as an emerging player. Stada Arzneimittel AG (parent) is listed as an others. Almus Pharmaceuticals is listed as a regional player.

Does EG Labo have an API?

No public API is recorded for EG Labo.

What industry is EG Labo in?

EG Labo's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales